Ocuphire Pharma has announced the acquisition of Opus Genetics to develop gene therapies for inherited retinal diseases (IRDs ...

Servier Canada has announced Health Canada's approval of VORANIGO for Grade 2 IDH-mutant glioma in adults and paediatric ...

The FDA has approved a new presentation of Alvotech and Teva’s SELARSDI, for the treatment of ulcerative colitis and Crohn's ...

This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...

Disruption is a pressing problem in the pharmaceutical world; patient health depends on clinical trial organisers avoiding it ...

For firms unsure about the digital transition, partnering with experienced providers like Controlant simplifies the process ...

The IOF highlights the importance of collaborative efforts in treating osteoporosis, ensuring appropriate care globally.